Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with non-small cell lung cancer (NSCLC) that can be surgically removed, at a stage classified as IIA through IIIB.
• People whose general health and ability to carry out daily activities is rated as 0 (fully active) or 1 (restricted in strenuous activity but able to do light work) on a standard medical scale.
• People whose organs (such as kidneys and liver) and bone marrow are functioning well enough to meet the trial's requirements.
• People who are able to provide a tumour tissue sample — either a new sample or one taken within the last 6 months — so that certain tumour markers (PD-L1 status, EGFR, and ALK) can be tested.
• People whose lungs are functioning well enough to meet the trial's requirements.

Who may not be able to join:

• People whose lung cancer has specific genetic changes known as EGFR mutations or ALK translocations.
• People whose tumour tests show a PD-L1 expression level below 1% (this applies to certain arms of the trial only — confirm with trial site).
• People who have, or have previously had, an autoimmune or inflammatory condition (such as rheumatoid arthritis or inflammatory bowel disease).
• People who have uncontrolled or serious ongoing health conditions, including uncontrolled high blood pressure, unstable chest pain (angina), uncontrolled irregular heartbeat, active bleeding disorders, serious ongoing gut conditions involving diarrhoea, or mental health or personal circumstances that would make it difficult to follow the trial requirements.
• People who have previously had another type of cancer (other than the current diagnosis).
• People whose lung cancer is classified as small-cell lung cancer or a mixed type that includes small-cell lung cancer.
• People who have a history of a condition where the immune system does not work properly from birth or early in life (primary immunodeficiency).
• People who have a history of non-infectious lung inflammation (interstitial lung disease or pneumonitis) that required steroid treatment, currently have this condition, or have possible lung inflammation that cannot be ruled out through scans taken at the start of the trial.
• People whose treatment plan includes radiotherapy before surgery.
• People whose surgeon determines at the outset that removing the tumour would require removal of an entire lung, or only a small segment or wedge of lung tissue, rather than a standard lobe removal.
• People whose heart's electrical activity measurement (a specific reading from an ECG called QTcF) is 470 milliseconds or higher.
• People for whom chemotherapy treatment is medically unsuitable based on standard prescribing guidelines.
• People who have moderate or severe heart or cardiovascular disease.
• People who are currently receiving any other chemotherapy, experimental treatment, biological therapy, or hormonal cancer therapy.
• People who have received a live vaccine within 30 days before the first dose of the trial treatment.
• People who have previously received certain types of immune-based cancer treatments, including anti-CTLA-4, anti-TIGIT, anti-PD-1, anti-PD-L1, anti-PD-L2 therapies, or treatments targeting certain other immune pathways (confirm specific agents with trial site).
• People who have previously been treated with a specific type of targeted drug called a TROP2-targeting antibody-drug conjugate, or a similar drug that works by blocking an enzyme called TOP1.
• People who are currently taking, or have taken within the last 14 days, medications that suppress the immune system.
• People who have an active or uncontrolled infection, including hepatitis B, hepatitis C, or HIV.

Important: Always verify eligibility with the trial site directly before applying.